El interés en corto de Mayville Engineering da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Mayville Engineering. Los datos de interés en corto se actualizan cada dos semanas.

Mayville Engineering (NYSE:MEC) Bolsa, Informe de interés en corto

Mayville Engineering

Mayville Engineering Co Inc is involved in a manufacturing partner that provides a broad range of prototyping and tooling, production fabrication, coating, assembly, and aftermarket components. Its customers operate in diverse end markets, including heavy- and medium-duty commercial vehicles, construction, power sports, agriculture, military, and other end markets. Its services comprise stamping, shearing, fiber laser cutting, forming, drilling, tapping, grinding, tube bending, machining, welding, assembly and logistic services.

Mayville Engineering Company, Inc. Common Stock

Mayville Engineering Co Inc

MEC Co Ltd

Menicon Co Ltd

MUSTANG ENERGY CORP by Mustang Energy Corp.

Mdf Commerce Inc Ordinary Shares

B of A Securities analyst Tal Liani maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Buy and raises the price target from $400 to $420.

News

Price Target

Analyst Ratings

CRWD

B of A Securities Maintains Buy on CrowdStrike Holdings, Raises Price Target to $420

SONM

Sonim Technologies Confirms No Talks With Orbic North America, Focuses On Evaluating Strategic Options

JNPR

Juniper Networks Unveils New Solution To Accelerate GPUaaS And AIaaS Deployment For Neocloud And AI Cloud Providers

Barrington Research analyst Gary Prestopino maintains CCC Intelligent Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCCS#NASDAQ">CCCS</a>) with a Outperform and maintains $14 price target.

CCCS

Barrington Research Maintains Outperform on CCC Intelligent Solutions, Maintains $14 Price Target

B of A Securities analyst Wamsi Mohan maintains DigitalOcean Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCN#NYSE">DOCN</a>) with a Underperform and raises the price target from $28 to $31.

DOCN

B of A Securities Maintains Underperform on DigitalOcean Holdings, Raises Price Target to $31

TJX Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) is looking for FY2026 GAAP EPS of $4.34-$4.43 vs $4.59 analyst estimate..

Guidance

TJX Companies Sees FY2026 GAAP EPS $4.34-$4.43 vs $4.59 Est

<ul>
<li>Senseonics and Ascensia integrate software between SweetSpot and Eversense 365, the world's first and only One Year CGM system</li>
<li>SweetSpot partners with endocrinology practices to provide virtual CGM monitoring and enhanced patient care</li>
</ul>

SENS

Senseonics And Ascensia Expand Diabetes Management Capabilities By Integrating SweetSpot With Eversense 365 CGM System

TJX Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) is looking for Q1 GAAP EPS of $0.87-$0.89 vs $0.98 analyst estimate..

TJX Companies Sees Q1 GAAP EPS $0.87-$0.89 vs $0.98 Est

General

AMCR

BERY

Amcor And Berry Global Group Announced That Shareholders Of Both Companies Voted To Approve The Combination Of These Two Companies, The Combination Is Well Advanced And Is Expected To Close In Mid Calendar Year 2025

Rosenblatt analyst Catharine Trebnick maintains CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) with a Buy and maintains $445 price target.

CYBR

Rosenblatt Maintains Buy on CyberArk Software, Maintains $445 Price Target

B of A Securities analyst Travis Steed maintains Solventum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>) with a Neutral and raises the price target from $80 to $85.

SOLV

B of A Securities Maintains Neutral on Solventum, Raises Price Target to $85

Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound for the treatment of multiple sclerosis ("MS"). It is a patented New Chemical Entity ("NCE") that has a unique mechanism of action. As shown in preclinical models of MS, it can directly stabilize the myelin sheath surrounding nerve fibers and thus provide protection from demyelination. MS is a disease characterized by demyelination, a process that causes progressive disability.

QNTM

Quantum Biopharma's Lucid-21-302 Passes Phase 1 Safety Review, Advancing Toward Phase 2 In MS Treatment

Rosenblatt analyst Barton Crockett maintains Liberty Formula One Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWONK#NASDAQ">FWONK</a>) with a Buy and maintains $102 price target.

FWONK

Rosenblatt Maintains Buy on Liberty Formula One Gr, Maintains $102 Price Target

PSTV

Plus Therapeutics Completes ReSPECT-LM Phase 1 Trial, Identifies Recommended Phase 2 Dose For CNS Cancer Treatment

SYTA

In Exchange For Outstanding Shares Of Core Gaming, Siyata Will Issue Common Shares To The Shareholders Of Core Gaming Based On Exchange Ratio Calculated As $160,000,000 Divided By Volume-Weighted Average Closing Price Of Siyata's Common Shares For 10-Day Trading Period Immediately Preceding Effective Time Of Merger

Lucid Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) is looking to unveil its new vehicles based on its midsize platform later this year or early next year, according to the company&#8217;s interim CEO Marc Winterhoff.
What Happened: Lucid is looking to bring three midsize vehicles to the market and the first of them is scheduled to start production in 2026, Winterhoff said.
The vehicles, he said, will be unveiled later this year or early next year. The company has completed the advanced engineering phase of two of the midsize vehicles, he said, while adding that they will now move on to the development and industrialization phase.
Both of Lucid&#8217;s current offerings &#8211; the <a href="https://www.benzinga.com/25/01/42842059/lucids-q4-deliveries-soar-to-new-highs-gravity-suv-sets-optimism-for-coming-months">Air sedan and the Gravity SUV</a>&#8211; are higher-end EVs with a high price point. While the base version of the Air sedan starts at $69,900, the only available Grand Touring variant of the Gravity starts at $94,900.
With the midsize platform, the company intends to expand its addressable market and increase delivery volumes. Lucid also intends to sell some of its midsize vehicles to the government of Saudi Arabia as part of a deal entered into in 2022.
Why It Matters: Lucid&#8217;s former CEO Peter Rawlinson has previously said that the high-volume midsize vehicle will start at around $48,000. A price point of $48,000 will put the vehicle in direct competition with Tesla Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) best-selling Model Y SUV.
It is unclear if all the three midsize vehicles that Lucid is planning will be priced in the same range. It is also not known whether the vehicle would be a sedan, SUV, or another form. 
A lower-priced sedan would also put Lucid in direct competition against Tesla&#8217;s cheapest offering, the Model 3 sedan which has a starting price of $42,490.
Lucid did not immediately respond to <a href="https://pro.benzinga.com/dashboard">Benzinga</a>&#8216;s request for comment. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43966461/lucid-to-up-production-increase-advertising-and-sell-in-saudi-arabia-to-up-high-end-gravity-suv-sales-this-year" target="_blank" rel="noreferrer noopener">Lucid Gravity Customers Opting For High-End Configurations, All The Way Up To $120,000: CEO Says SUV ‘Attracting New People To The Brand'</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

LCID

TSLA

Lucid Prepares To Launch Affordable EVs: First Midsize Model Could Be Unveiled As Early As This Year To Take On Elon Musk's Tesla

As part of the agreement, Tollo will assist Wellgistics LLC in preparing materials to market Tollo's emerging suite of products to Wellgistics LLC's network of pharmacies by generating healthcare practitioner-tailored content to help them educate client physicians, physician groups and patients on how to optimize patient outcomes by incorporating these select medical foods into patients' treatment regimens. Medical foods are specialized foods, to be taken under the supervision of a physician, that are for the dietary management of certain health conditions. Wellgistics LLC's objective of marketing Tollo's medical foods is to provide patients with the dietary support they need to get the most out of prescription drugs and other treatment modalities used by their physicians to help manage complex chronic conditions.

WGRX

Wellgistics Expands Healthcare Offerings With Tollo Health Deal, Targeting GLP-1 and Long COVID Markets

KELYA

Kelly Launches Integrated Permanent Hiring Solutions Business, Combining KellyOCG And Motion Recruitment Partners' Brands

MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.60) by 20 percent. This is a 620 percent decrease over losses of $(0.10) per share from the same period last year.

Earnings

MLTX

MoonLake Q4 2024 GAAP EPS $(0.72) Misses $(0.60) Estimate, Year-end Cash, Cash Equivalents And Short-term Marketable Debt Securities Of $448M Expected To Providing Cash Runway To At Least The End Of 2026

Comments

Mayville Engineering

Interés en corto

Mayville Engineering (NYSE:MEC) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL